A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 4, 2016, Pages 377-388

  Gaida, Razia ^a   Truter, Ilse ^a   Grobler, Christoffel ^a,b   Kotze, Theunis ^a   Godman, Brian ^c,d  

^a NELSON MANDELA METROPOLITAN UNIVERSITY   (South Africa)

^b Elizabeth Donkin Hospital   (South Africa)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

efavirenz; HIV; neuropsychiatric side effects; pharmacovigilance; systematic review

Indexed keywords

ABACAVIR; ABACAVIR PLUS DOLUTEGRAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE; COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; RALTEGRAVIR; RILPIVIRINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ABNORMAL DREAMING; AGE DISTRIBUTION; ANXIETY; BEDTIME DOSAGE; CONCENTRATION LOSS; DEPRESSION; DISEASE SEVERITY; DIZZINESS; HALLUCINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MENTAL DISEASE; MENTAL INSTABILITY; NEUROLOGIC DISEASE; PARANOIA; REVIEW; SEX DIFFERENCE; SLEEP QUALITY; SOUTH AFRICA; SUICIDAL IDEATION; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; HIV INFECTIONS; SLEEP DISORDER;

ANTI-HIV AGENTS; ANXIETY; BENZOXAZINES; DEPRESSION; DIZZINESS; HIV INFECTIONS; HUMANS; SLEEP WAKE DISORDERS;

EID: 84962569327     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2016.1157469     Document Type: Review

References (39)

1. National consolidated guidelines for the prevention of mother-To-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. Pretoria: The National Department of Health; 2015. p. 119
2. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011; 15 (8): 1803-1808
3. Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev. 2009; 11 (2): 103-109
4. Gutierrez-Valencia A, Viciana P, Palacios R, et al. Stepped-dose versus full dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. Ann Intern Med. 2009; 151 (3): 149-156
5. Clifford DB, Evans S, Yang Y, et al. Long-Term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials. 2009; 10 (6): 343-355
6. Fumaz CR, Munoz-Moreno JA, Molto J, et al. Long-Term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychological issues, and adherence. J Acq Immun Def Synd. 2005; 38 (5): 560-565
7. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz-And protease inhibitor-Treated patients. HIV Clin Trials. 2005; 6 (4): 187-196
8. Adco-Efavirenz [package insert]. Midrand (Gauteng): Adcock Ingram; 2007
9. Blanch J, Martinez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acq Immun Def Synd. 2001; 27 (4): 336-343
10. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005; 143 (10): 714-721
11. Gutierrez F, Navarro A, Padillo S, et al. Prediction of neuropsychiatric adverse events associated with long-Term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005; 41 (11): 1648-1653
12. Hoffman CJ, Fielding KL, Charalambous S, et al. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS. 2008; 2 (1): 670-674
13. Leutscher PDC, Stecher C, Storgaard M, et al. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scand J Infect Dis. 2013; 45 (8): 645-651
14. Lochet P, Peyrière H, Lotthé A, et al. Long-Term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003; 4 (1): 62-66
15. Nelson M, Stellbrink H, Podzamczer D, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS. 2011; 25 (3): 335-340
16. Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med. 2006; 7 (8): 544-548
17. Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDs. 2006; 20 (8): 542-548
18. Naidoo P, Chetty VV, Chetty M. Impact of CYP polymorphisms, ethnicity, and sex differences in metabolism on dosing strategies: the case of efavirenz. Eur J Clin Pharmacol. 2014; 70 (4): 379-389
19. Napoli AA, Wood JJ, Coumbis JJ, et al. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. J Int AIDS Soc. 2014; 17: 19214
20. Smith C, Ryom L, dArminio Monforte A, et al. Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. J Int AIDS Soc. 2014; 17 (4suppl3): 19512
21. Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med. 2014; 161 (1): 1-10
22. Von Giesen HJ, Köller H, De Nocker D, et al. Long-Term safety and efficacy of NNRTI within the central nervous system. HIV Clin Trials. 2003; 4 (6): 382-390
23. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Panel on antiretroviral guidelines for adult and adolescents. Department of Health and Human Services; 2015
24. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. British HIV Association; 2015
25. Unicef. Eastern and Southern Africa HIV and AIDS. [. cited 2015 Dec 27 ]. Available from: http://www.unicef.org/esaro/5482-HIV-AIDS.html
26. Botswana national HIV and AIDS treatment guidelines. Gaborone: Ministry of Health; 2012. p. 197. Available from: http://www.med.upenn.edu/botswana/user-documents/BotsNatHIV-AIDSTreatGuide WEB22-05-2012.pdf
27. National guidelines on the use of antiretroviral therapy for HIV prevention and treatment. Lesotho: Ministry of Health; 2014. p. 140. Available from: http://www.emtct-iatt.org/wp-content/uploads/2015/02/National-ART-Guidelines-Final-16-June-20142.pdf
28. Clinical management of HIV in children and adults. Malawi: Ministry of Health; 2014. p. 105. Available from: http://www.emtct-iatt.org/wp-content/uploads/2015/09/Malawi-HIV-Guidelines-2014.pdf
29. National guidelines for antiretroviral therapy. Republic of Namibia Ministry of Health and Social Services; 2010. p. 90. Available from: http://www.who.int/hiv/pub/guidelines/namibia-art.pdf
30. National comprehensive HIV package of care for adults and adolescents in Swaziland. Kingdom of Swaziland: Ministry of Health; 2010. p. 174. Available from: http://www.who.int/hiv/pub/guidelines/swaziland-art.pdf
31. National comprehensive HIV package of care for adults and adolescents in Swaziland. Kingdom of Swaziland: Ministry of Health; 2015. 165p.
32. Antiretroviral therapy for HIV infection in adults and adolescents recommendations for a public health approach. World Health Organisation: Austria; 2010. 156p.
33. The World Bank Data: Country and Lending Groups. 2015. Available form: http://data.worldbank.org/about/country-And-lending-groups
34. Guidelines for antiretroviral therapy for the prevention and treatment of HIV in Zimbabwe. Harare: The National Medicine and Therapeutics Policy Advisory Committee and The AIDS and TB Directorate, Ministry of Health and Child Care; 2013. p. 88. Available from: http://www.nac.org.zw/sites/default/files/2013%20Zimbabwe%20ARV%20Guidelines%20%20Main%20Document%20(1).pdf
35. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS. 2001; 15 (1): 71-75
36. Ngaimisi E, Habtewold A, Minzi O, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan African populations. PLoS ONE. 2013; 8 (7): e67946
37. Massele A, Burger J, Katende-Kyenda NL, et al. Outcome of the first medicines utilization research in Africa group meeting to promote sustainable and rational medicine use in Africa. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):885-888
38. AVERT. HIV and AIDS in sub-Saharan Africa regional overview. [. cited 2015 Aug 20 ]. Available from: http://www.avert.org/professionals/hiv-Around-world/sub-saharan-Africa/overview
39. Leclerc-Madlala S. Age-disparate and intergenerational sex in southern Africa: the dynamics of hypervulnerability. AIDS (London, England). 2008; 22 (Suppl 4): S17-25